Amundi’s Coherus Oncology CHRS Stock Holding History

Amundi’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-7,765	Closed	-$34.3K	–	2013
2023 Q2	$34.3K	Sell	7,765 -1,020	-12%	-$6.02K	﹤0.01%	1928
2023 Q1	$67.5K	Buy	+8,785	New	+$68.2K	﹤0.01%	1831
2021 Q3	–	Sell	-10,994	Closed	-$152K	–	1575
2021 Q2	$152K	Buy	+10,994	New	+$156K	﹤0.01%	1430

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Amundi's CHRS Position: Q3 2023 in Review

Amundi sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 7,765 shares — an estimated $34.3K sold.

Amundi first reported a position in CHRS in Q2 2021 and held it in 3 quarters. The position peaked at $152K in Q2 2021. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

Amundi reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
Amundi sold 7,765 Coherus Oncology shares in Q3 2023, an estimated $34.3K.
Amundi first reported a position in Coherus Oncology in Q2 2021 and held it in 3 quarters.
Amundi's Coherus Oncology position peaked at $152K in Q2 2021.
169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Amundi's 13F filing for Q3 2023, filed 14 Nov 2023.